Results 131 to 140 of about 32,822 (166)

Dual Antiplatelet Therapy or Dual Pathway Inhibition

Thrombosis and Haemostasis, 2023
Shinya Goto, Shinichi Goto
openaire   +2 more sources

Dual antiplatelet therapy escalation and de-escalation

European Heart Journal: Acute Cardiovascular Care
Abstract Dual antiplatelet therapy (DAPT) remains a key element of secondary prevention after percutaneous coronary intervention. However, its optimal duration and intensity continue to pose challenges due to the trade-off between ischaemic protection and bleeding risk.
Antonio Greco, Giacinto Di Leo, Simone Finocchiaro, Antonino Imbesi, Davide Capodanno   +4 more
openaire   +2 more sources

The dual-therapy Combo Stent: A Rationale for a Light Dual Antiplatelet Therapy Treatment

Future Cardiology, 2018
The COMBO stent is a new, sirolimus-eluting bioresorbable polymer, bioengineered stent. This technology combines the advantages of second-generation drug-eluting stents with the endothelial progenitor cell capture technology mediated by the anti-CD34 antibody coating on the COMBO luminal surface.
Luca, Baldetti, Alessandro, Beneduce, Mario, Gramegna, Antonio, Colombo, Francesco, Giannini   +4 more
openaire   +2 more sources

A safer bet for MitraClip: Choosing between single antiplatelet therapy and dual antiplatelet therapy

International Journal of Cardiology
Optimal antithrombotic therapy after mitral valve transcatheter edge-to-edge repair (TEER) remains uncertain.To compare the efficacy and safety of single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) in mitral TEER recipients.We retrospectively queried the TriNetX Global Network, identifying 3325 adult patients who underwent ...
Yaman, Jarrar, Laith, Alomari, Emmanuel, Otabor, Justin, Lam, Layla, Ellayyan, Mohamad, Abboud, Jaspreet, Singh, Jana, Alomari   +7 more
openaire   +2 more sources

Dual Antiplatelet Therapy

JAMA, 2019
Khaled M, Ziada, David J, Moliterno
openaire   +2 more sources

[New antiplatelet agents and the question of dual antiplatelet therapy].

Der Internist, 2012
The introduction of clopidogrel for use with aspirin (ASA) as a dual antiplatelet therapy has markedly reduced the risk of atherothrombotic vessel occlusion in patients with acute coronary syndromes (ACS). However, stronger antiplatelet therapy has also been associated with significant increases in severe bleeding, resulting in no change in mortality ...
openaire   +1 more source

Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Stroke, 2021
Moira Kapral, William Whiteley, Lester Leung   +2 more
exaly  

Dual antiplatelet therapy duration and mortality

The Lancet, 2015
Johann, Auer, Robert, Berent, Franz, Gurtner   +2 more
openaire   +2 more sources

Effects of dual antiplatelet therapy on graft patency after lower extremity bypass

Journal of Vascular Surgery, 2021
Scott Damrauer, Venkat Kalapatapu, Julia Glaser   +2 more
exaly  

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery

Journal of the American Heart Association, 2021
Shen Lin, Jianyu Qu, Zhe Zheng
exaly